"The other point to note is that as much as these results may be amazing.. they are specific to keytruda and cavatak..
That goes against the possabilities of another company bidding without results relating to their drugs.. "
So doesn't improving BristolMS's drug by over 400% count then?
The two drugs that CAVATAK has been combined with have both shown increased efficacy and much better safety data. Safety is a big issue with these drugs (hence the need for imu (plug when you can)).
That could indicate that CAVATAK would also help similar drugs.
cheers
VLA Price at posting:
$1.70 Sentiment: Buy Disclosure: Held